BMY — BRISTOL MYERS SQUIBB CO
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 14272 ·
Last close
$61.35
Market Cap
$125.40B
52W High
$67.94
52W Low
$43.34
ADV30
11,381,959
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 13,069,000,000 | 8,923,000,000 | 4,401,000,000 | 2,162,000,000 | 88,772,000,000 | 9,574,000,000 | 65,368,000,000 |
| Jun 2026 | 12,973,000,000 | 9,247,000,000 | 4,025,000,000 | 3,317,000,000 | 87,634,000,000 | 8,722,000,000 | 65,315,000,000 |
| Mar 2026 | 11,489,000,000 | 8,068,000,000 | 3,365,000,000 | 2,677,000,000 | 86,476,000,000 | 9,574,000,000 | 66,374,000,000 |
| Dec 2025 | 12,503,000,000 | 8,406,000,000 | 2,813,000,000 | 1,087,000,000 | 90,038,000,000 | 10,209,000,000 | 71,532,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$10,652,000,000
Investing CF
$-5,307,000,000
Financing CF
$-11,441,000,000
CapEx
$-1,366,000,000
Dividends Paid
$-5,119,000,000
Buybacks
—
EPS Diluted TTM
$4.51
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$21,190,000,000
Inventory
$2,704,000,000
Receivables
$12,851,000,000
ST Investments
$3,007,000,000
EBIT TTM
$12,985,000,000
Pretax Income TTM
$11,332,000,000
Interest Exp TTM
$1,653,000,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$50,033,999,872
EBITDA
$19,044,999,168
Free Cash Flow
$8,114,375,168
Enterprise Value
$161,614,807,040
Total Cash
$11,066,999,808
Total Debt
$45,053,001,728
Shares Out
2,044,085,831
Trailing EPS
$4.51
Book Value
$10.93
ROE
46.6%
ROA
10.7%
Div Yield
4.03%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,195,000,000 | 13,724,000,000 | 7,054,000,000 | 90,038,000,000 | 71,532,000,000 | 18,473,000,000 | 14,156,000,000 |
| Dec 2024 | 48,300,000,000 | 5,887,000,000 | -8,948,000,000 | 92,603,000,000 | 76,215,000,000 | 16,335,000,000 | 15,190,000,000 |
| Dec 2023 | 45,006,000,000 | 8,195,000,000 | 8,025,000,000 | 95,159,000,000 | 65,674,000,000 | 29,430,000,000 | 13,860,000,000 |
| Dec 2022 | 46,159,000,000 | 9,104,000,000 | 6,327,000,000 | 96,820,000,000 | 65,702,000,000 | 31,061,000,000 | 13,066,000,000 |
TTM Snapshot
Revenues TTM
$49,186,000,000
NetIncome TTM
$9,282,000,000
OpCashFlow TTM
—
Assets (Latest)
$87,634,000,000
Forward EPS
$6.63
Max Pain — expiry 2026-11-27
max pain strike: $62.00 · spot: $59.56 · call oi: 2,326 · put oi: 7,339
Expected Move to 2026-11-27:
±$2.80
(4.70%) —
implied range
$56.76 –
$62.36
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $135.44B | $534.20 | — |
| NVO | NOVO NORDISK A S | $136.10B | $40.70 | — |
| SNY | Sanofi | $113.89B | $47.53 | — |
| GSK | GSK plc | $98.62B | $49.24 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $97.34B | $957.76 | — |
News headlines (Yahoo Finance, 1h cache)
Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors
2026-11-18 20:20 · Yahoo
Missed Bristol-Myers Squibb's Rally? Here's What Early Buyers Saw
2026-11-18 17:11 · Yahoo
Altria or Bristol Myers Squibb: The One Dividend Stock I’d Hold for the Next 20 Years
2026-11-18 15:23 · Yahoo
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
2026-11-18 14:10 · Yahoo
Bristol Myers Stock's Dividends Couldn't Close The Gap
2026-11-18 12:44 · Yahoo
Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer
2026-11-18 11:43 · Yahoo
Bristol Myers Squibb CEO says America’s edge in new drugs is ‘not a birthright’ as the U.S. loses its measles elimination status
2026-11-18 08:00 · Yahoo
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
2026-11-17 23:40 · Yahoo
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
2026-11-17 13:00 · Yahoo
Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
2026-11-18 18:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.